Page last updated: 2024-11-02

pirenzepine and Hepatitis B, Chronic

pirenzepine has been researched along with Hepatitis B, Chronic in 1 studies

Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.

Hepatitis B, Chronic: INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tamam, L1
Yerdelen, D1
Ozpoyraz, N1

Other Studies

1 other study available for pirenzepine and Hepatitis B, Chronic

ArticleYear
Psychosis associated with interferon alfa therapy for chronic hepatitis B.
    The Annals of pharmacotherapy, 2003, Volume: 37, Issue:3

    Topics: Adult; Antipsychotic Agents; Antiviral Agents; Benzodiazepines; Hepatitis B, Chronic; Humans; Interf

2003